InvestSMART

Alterity Therapeutics Limited (ASX:ATH)

ALERT: Price-sensitive ASX Announcement for ATH
Current share price for ATH : $0.750 0.742 (9,275%)+
Announcement
Release
26 Feb 2026 9:19AM
Price at Release
$0.008
Full Release
download
Summary
Alterity Therapeutics Limited made significant progress in developing ATH434 for Multiple System Atrophy (MSA) during the half-year ended 31 December 2025. The company conducted successful Phase 2 clinical trials, confirming ATH434's potential efficacy and safety. They prepared for an End-of-Phase-2 meeting with the FDA in mid-2026 and raised approximately A$20 million to support regulatory and clinical activities. Despite a net loss of $9,615,849, the company strengthened its financial position with cash and cash equivalents amounting to $49,200,547 by the end of the period. Alterity continued to seek strategic partnerships and external interest in ATH434's commercial viability, while maintaining a focus on potential market expansion.
Key Points
  • During the half-year ended 31 December 2025, Alterity Therapeutics advanced its lead asset, ATH434, for treating Multiple System Atrophy (MSA).
  • The company reported a net loss of $9,615,849 for the half-year ended 31 December 2025.
  • Alterity's regulatory strategy focused on preparations for an End-of-Phase-2 meeting with the FDA for mid-2026.
  • ATH434 Phase 2 studies showed clinically meaningful efficacy and safety in treating MSA.
  • The company raised approximately A$20 million in September 2025 for ATH434 development activities.
  • Alterity engaged in strategic partnerships and external interest for ATH434's commercial potential.
  • No dividends were paid or declared during the period ending 31 December 2025.
  • The company maintains a going concern basis, with cash and cash equivalents of $49,200,547 as of 31 December 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.